GLP-1s Now Seen as Tool for Modulating Aging

Originally developed to treat type 2 diabetes, the first GLP-1 agonist, exenatide (Byetta), was approved by the FDA in 2005. This class of drugs mimics the effects of the natural gut hormone GLP-1, which stimulates insulin production and slows digestion, with a key advantage over older diabetes medications being a lower risk of hypoglycemia. It wasn't until 2014 that the FDA approved a GLP-1, liraglutide (Saxenda), specifically for weight loss, marking a pivotal shift in its application. The anti-aging potential of these drugs is linked to their ability to combat chronic low-grade inflammation, a major driver of age-related diseases. In the SELECT trial, semaglutide significantly reduced high-sensitivity C-reactive protein (CRP), an established biomarker of inflammation, independent of weight loss. Studies have shown that semaglutide can lower inflammatory markers like CRP by up to 43%, an effect enhanced by the reduction of visceral fat, the metabolically dangerous fat surrounding organs. At a cellular level, GLP-1 agonists appear to improve the function of mitochondria, the energy-producing structures in our cells whose decline is a hallmark of aging. Preclinical studies show that drugs like liraglutide can increase the number of mitochondria and enhance their respiratory function. This improvement in cellular energy metabolism and reduction of oxidative stress may protect against a range of age-related conditions. The cardiovascular benefits are among the most well-documented, with major clinical trials demonstrating significant reductions in heart attack, stroke, and cardiovascular death. The LEADER and SUSTAIN-6 trials, for example, showed double-digit reductions in major adverse cardiovascular events. These protective effects on the heart and blood vessels are seen even in individuals without diabetes, pointing to mechanisms beyond just glucose control. Beyond metabolic and cardiovascular health, research is now exploring the neuroprotective effects of GLP-1s. Preclinical models suggest these drugs can reduce amyloid and tau pathology, key factors in Alzheimer's disease, and lower neuroinflammation. Observational studies in humans have linked semaglutide use to a 40-70% lower risk of an Alzheimer's diagnosis. The impact on kidney health is another critical area of investigation, as kidney function often declines with age. A 2025 meta-analysis covering over 85,000 participants found that these drugs reduced the risk of kidney failure by 16% and slowed the decline in filtration rate. The FLOW clinical trial specifically found that semaglutide reduced the risk of progression of chronic kidney disease by 24%. Recent studies are even using "epigenetic clocks" to measure biological aging at a molecular level. In a trial with people living with HIV, a group known to experience accelerated aging, semaglutide was found to significantly slow the rate of aging as measured by DNA methylation. Specifically, the mortality-linked PCGrimAge clock showed a deceleration, suggesting a fundamental impact on the aging process itself. While the potential is significant, researchers note that these are not a replacement for a healthy lifestyle and that preserving muscle mass during weight loss is critical for healthy aging. The focus of ongoing research is to determine optimal dosages, long-term safety, and how these drugs might be used to extend "healthspan"—the number of years lived in good health.